The US Food and Drug Administration recently granted approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The traditional approval comes after tisotumab vedotin-tftv was given accelerated approval for this indication.
Advertisement
Lenvatinib is a common treatment for patients with uHCC, and has been used with pembrolizumab for other diseases.
The FDA has approved Cyltezo, for the treatment of chronic inflammatory diseases.
A study reported on dual-drug resistance in a kidney transplant patient who received sotrovimab and remdesivir for COVID-19.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
Researchers analyzed the utilization and outcomes of multigene panel GT in patients with PDAC.
Nephrology Times will cover the National Kidney Foundation Spring Clinical Meetings 2024 live and onsite.
The National Kidney Foundation will honor distinguished health care professionals at the 2024 Spring Clinical Meetings.
A brief episode of anger triggered by a past experience has the potential to increase the risk of stroke.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Lenvatinib is a common treatment for patients with uHCC, and has been used with pembrolizumab for other diseases.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.Researchers analyzed the utilization and outcomes of multigene panel GT in patients with PDAC.
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
The Latest From Heme Today
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
